Is Ocugen Inc stock halal to invest in?

Company Name
Company Symbol
Exchange
Ocugen Inc
OCGN
NASDAQ
OCGN
Not Halal
Ocugen Inc
NASDAQ

Warning: The result may change based on other methodologies. As of the recent update on Wednesday 11th of June 2025 , is considered as Not Halal based on FTSE methodology. To access full report and unlock the detailed results with associated ratios for 5 halal investment methodologies, you can click below.

Detailed report based on FTSE methodology

Activity filter

Main Activity
Activity test result
Biotechnology
PASS

Ocugen Inc

Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is involved in the development of OCU200, a novel fusion protein for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.

Financial filter

Debt test

Total Debt
Interest free debt
Adjusted debt level
Total Asset
Debt Ratio
PASS or FAIL
48546000
0
48546000
64460000
75.31%
FAIL

Cash test

Cash
Cash Eq.
Short Term Investment
Total Asset
Cash & Eq. ratio
PASS or FAIL
37800000
0
0
64460000
58.64%
FAIL

Acid test

Cash
Cash Eq.
Net Accounts Receivables
Total Asset
Quick ratio
PASS or FAIL
37800000
0
0
64460000
58.64%
FAIL

Non permissible income filter

Net Interest Income (Expense) as non-Operating

Total Non permissible and doubtful income
Total revenue
Non permissible and doubtful income ratio
PASS or FAIL
0
1481000000000
0%
PASS